Aurobindo Pharma USA Completes Acquisition of Lannett Company, Bolstering Pharmaceutical Portfolio
Aurobindo Pharma USA Inc., a wholly owned subsidiary of Aurobindo Pharma Limited, has announced the successful completion of its acquisition of Lannett Company, Inc., from Lannett Seller Holdco, Inc. This strategic move follows securing approval from the U.S. Federal Trade Commission on June 18, 2026.Effective June 29, 2026, Lannett has officially become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC.
The integration process between the two entities is set to commence immediately. The company emphasized that its immediate focus includes ensuring uninterrupted access to critical medications, sustaining trusted relationships with partners, and providing support to employees throughout the transition period. By combining their respective capabilities and resources, the organization aims to enhance the availability of essential medicines and deliver sustained, long-term value to customers, stakeholders, and patients.
In addition to the acquisition completion, APUSA welcomed more than 400 Lannett employees into its organization. This influx strengthens APUSA's operational capabilities and talent base. The management team extended sincere appreciation to Lannett's leadership for enabling a smooth transition and for their valuable contributions to the newly combined entity.
AUROPHARMA Stock Price Movement
Shares of Aurobindo Pharma Limited are surging to ₹1577.9 as of 10:02 AM today, edging up 1.96% in live trading. The rally sees intense volume, with the stock commanding a significant intraday high and logging 398,490 shares traded so far this morning.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.